ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in St Louis, MO

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near St Louis, MO, USA:

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14)

This study will look to establish the recommended biologic dose of AE37 in combination with pembrolizumab that will enhance the tumor-specif-...

Active, not recruiting
Triple-negative Breast Cancer
Biological: Pembrolizumab
Biological: AE37 Peptide vaccine

Phase 2

NuGenerex Immuno-Oncology

Swansea, Illinois, United States and 5 other locations

of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Trastuzumab deruxtecan

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Saint Louis, Missouri, United States and 31 other locations

and nivolumab with neoadjuvant chemotherapy will decrease tumor associated macrophages (TAMs) and increase tumor infiltrating lymph-...

Active, not recruiting
Triple Negative Breast Cancer
Procedure: Tumor biopsy
Biological: Cabiralizumab

Phase 1, Phase 2

The Washington University
The Washington University

Saint Louis, Missouri, United States

doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Atezolizumab
Drug: Placebo

Phase 3

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Swansea, Illinois, United States and 216 other locations

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Saint Louis, Missouri, United States and 160 other locations

for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...

Enrolling
Breast Cancer
Drug: Tobemstomig
Drug: Nab-Paclitaxel

Phase 2

Roche
Roche

Saint Louis, Missouri, United States and 109 other locations

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Enrolling
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Saint Louis, Missouri, United States and 360 other locations

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...

Enrolling
Breast Cancer
Drug: Paclitaxel
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Saint Louis, Missouri, United States and 286 other locations

(ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and ...

Active, not recruiting
Advanced Solid Tumors
Non-small-cell-lung-cancer (NSCLC)
Drug: ABBV-368
Drug: ABBV-927

Phase 1

AbbVie
AbbVie

Saint Louis, Missouri, United States and 25 other locations

(HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), esophageal squamous cell carcinoma (ESCC), triple negative...

Enrolling
Triple Negative Breast Cancer
Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Drug: ABBV-400

Phase 1

AbbVie
AbbVie

Saint Louis, Missouri, United States and 39 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems